January 25 - 29, 2006
Marriott’s Rancho Las Palmas Resort & Spa
Rancho Mirage, California
José Baselga, Vall d’Hebron University Hospital, Barcelona, Spain
Sara A. Courtneidge, The Burnham Institute, La Jolla, California
Paul Workman, The Institute of Cancer Research, Surrey, England
Laboratory scientists interested in the genetic and molecular basis of cancer and investigators focused on the translational clinical aspects of the disease from over a dozen countries gathered to discuss the latest advances in combination therapies targeted to the multiple molecular abnormalities involved in human cancer. With the development of effective molecular therapeutics to oppose the effects of cancer-causing genes and the signal transduction pathways and biological processes they hijack, ‘drugging the cancer genome’ has become a reality.
Sessions focused on clinical challenges combining molecular therapeutics with cytotoxics, pathways and models for evaluating drug combinations, new high throughput screening approaches for discovering genome targets and combination therapies, targeting molecular dependence or oncogene addiction, targets with combinatorial downstream effects, combinations with signal transduction inhibitors, the PI3 kinase/AKT/mTOR pathway, other novel approaches, and understanding and exploiting the cancer genome sequence.
*(Adobe Acrobat Reader required)
Please visit the AACR Meeting Calendar for a complete list of upcoming programs.